CurebaseDemo
    New ArticleRead Article →
    Back to Resources

    Clinical Trial Authorization (CTA): Global Guide 2026

    clinical trial authorization

    Getting a new, potentially life saving therapy from the lab to patients is a long and complex journey. At the heart of this process is the clinical trial authorization, the official green light from regulatory bodies that allows researchers to begin testing an investigational product in humans. It’s a critical checkpoint that ensures studies are safe, ethical, and scientifically sound.

    Navigating the web of regulations can be daunting, as the requirements for a clinical trial authorization vary significantly from one region to another. This guide breaks down the essential authorization processes in the European Union, the United Kingdom, and the United States, giving you a clear roadmap of what to expect.

    The New Era of EU Clinical Trial Authorization

    For years, running multinational trials in Europe meant submitting separate applications in each country, a process that was often slow and complex. That all changed with the EU Clinical Trial Regulation 536/2014 (CTR), which has completely modernized the approach to gaining clinical trial authorization across the European Union.

    What is the Clinical Trials Information System (CTIS)?

    The engine driving this change is the Clinical Trials Information System, or CTIS. Developed by the European Medicines Agency, CTIS is the single online portal where sponsors submit and manage their trial applications for all EU member states. It’s the backbone of the new regulation, creating a unified and transparent system for both regulators and the public. Since January 31, 2023, using CTIS has been mandatory for all new clinical trial applications in the EU.

    The Power of a Single Application for Multinational Trials

    The most significant advantage of the CTR and CTIS is the ability to submit a single application for multinational authorization. Instead of juggling dozens of separate submissions, sponsors can now use one coordinated application to seek approval in multiple EU countries at once.

    Here’s how it works:

    • One Dossier: Sponsors submit one set of documents through CTIS for all desired countries.
    • Coordinated Review: One member state takes the lead on the scientific review, collaborating with other involved nations.
    • Harmonized Decision: Each country still gives a final national decision, but it happens within a synchronized timeline based on the shared assessment.

    This streamlined process dramatically accelerates the startup phase for multinational studies, making Europe a more attractive location for innovative research. Pairing the CTR process with modern decentralized clinical trial technology can further speed startup and oversight.

    Key Dates in the CTR and CTIS Transition

    The shift to the new system was phased in over several years to give everyone time to adapt.

    • January 31, 2022: The CTR became applicable, and CTIS went live. Sponsors could choose to use the new system or the old national ones.
    • January 31, 2023: CTIS became the only way to submit new applications for clinical trial authorization.
    • January 31, 2025: All ongoing trials, even those started under the old rules, must be transitioned into CTIS. Maintaining a complete electronic trial master file (eTMF) is crucial during this transition.

    Navigating Clinical Trial Authorisation in the UK (MHRA)

    In the United Kingdom, the key to starting a study is securing a Clinical Trial Authorisation (CTA) from the Medicines and Healthcare products Regulatory Agency (MHRA). This is the UK’s formal regulatory approval for testing an investigational medicinal product in humans.

    Since January 2022, the UK has operated a “Combined Review” system. This brilliant move integrates the MHRA’s regulatory assessment with the Research Ethics Committee (REC) review. Sponsors submit a single application and receive one unified decision, which covers both regulatory and ethical approval. This reform has been a remarkable success, with recent data showing the average UK clinical trial authorization time has been nearly halved from 91 days to just 41 days.

    However, getting it right the first time is key. The MHRA reports that more than half of all CTA applications initially require more information before they can be approved. Working with experts who understand these common issues can prevent unnecessary delays.

    The Core Components of Ethical and Local Approval

    Beyond the main regulatory bodies, two other layers of approval are universally required before a single patient can be enrolled: ethical review and site readiness confirmation.

    The Role of the Research Ethics Committee (REC)

    A Research Ethics Committee (REC), known as an Institutional Review Board (IRB) in the US, is an independent body that protects the rights and welfare of trial participants. REC approval is a non negotiable legal and ethical requirement. The committee, made up of scientific and non scientific members, reviews the trial protocol, informed consent documents, and investigator qualifications to ensure:

    • Risks to participants are minimized and justified by potential benefits.
    • The informed consent process is clear, comprehensive, and truly voluntary.
    • Participants are protected and treated ethically throughout the study.

    An REC can approve a study, request modifications, or disapprove it altogether.

    Securing Site Research and Development (R&D) Approval

    Site R&D approval is the final green light given by the local institution, like a hospital or clinic, where the trial will actually take place. This internal check confirms that the site has the “capacity and capability” to run the study successfully. The R&D office verifies that the site has the right staff, facilities, equipment, and financial arrangements in place. Recruitment cannot begin at a site until this local R&D approval is granted. When you’re ready to activate sites, dedicated clinical trial patient recruitment support can accelerate enrollment.

    Platforms like Curebase’s eClinical software help manage these complex workflows, keeping regulatory documents and contracts organized to help expedite approvals across multiple sites.

    The Investigational New Drug (IND) Application in the US

    In the United States, the pathway to clinical trial authorization is the Investigational New Drug (IND) application, submitted to the Food and Drug Administration (FDA). An IND is the legal gateway that allows an unapproved drug or biologic to be shipped across state lines and administered to humans in a clinical study.

    What Goes Into an IND Application?

    An IND is a comprehensive data package designed to convince the FDA that a proposed trial is reasonably safe to proceed. Much of this information is organized within an Electronic Data Capture (EDC) platform. The key components include:

    • Preclinical Data: Results from animal pharmacology and toxicology studies that support the safety of the proposed human dose.
    • Manufacturing Information (CMC): Details on how the drug is produced, its composition, and its stability to ensure a quality product.
    • Clinical Protocols: A detailed plan for the proposed study, including its design, endpoints, and safety monitoring procedures supported by ePRO/eCOA solutions.
    • Investigator Information: Qualifications of the clinical investigators who will conduct the study.

    The FDA’s 30 Day Safety Review Period

    Once an IND is submitted, a 30 calendar day safety review period begins. During this time, FDA experts scrutinize the application to identify any unreasonable risks to human subjects. If the FDA does not contact the sponsor with concerns or place the study on “clinical hold” within those 30 days, the sponsor can begin the trial (assuming they also have IRB approval). Essentially, no news from the FDA is good news.

    Getting Ahead with the Pre IND Consultation Program

    To avoid potential holds or delays, the FDA encourages sponsors to use its Pre IND Consultation Program. This allows sponsors to have a formal meeting with the FDA before submitting the IND. It’s a valuable opportunity to get agency feedback on study design, preclinical data, and other critical elements, which helps de risk the final submission. One organization used a Pre IND meeting to get FDA input on their animal study data, ensuring their development plan was on the right track before filing.

    Different Types of INDs for Different Needs

    Not all INDs are the same. The FDA has different categories to fit specific situations, from broad research programs to urgent, individual patient needs.

    Investigator, Emergency, and Treatment INDs Explained

    There are three main types of INDs:

    • Investigator IND: Submitted by a physician researcher who is both sponsoring and conducting a study, often to explore a new use for an approved drug or a novel compound.
    • Emergency Use IND (eIND): Used in life threatening situations where there is no time for a full IND review. This allows a physician to use an experimental drug for a single patient in a critical emergency, with FDA authorization often granted over the phone.
    • Treatment IND: This mechanism expands access to a promising investigational drug for patients with serious conditions who are not in a clinical trial. It’s typically used later in development when there is evidence the drug may be effective.

    A Closer Look at Emergency Use and Single Patient INDs

    Emergency Use and Single Patient INDs fall under the FDA’s “expanded access” or “compassionate use” programs. They provide a critical pathway for patients who have exhausted all other options.

    An Emergency Use IND is for the most urgent cases. The FDA can provide verbal authorization in hours to treat a patient facing immediate, life threatening harm. Paperwork follows after the fact.

    A Single Patient IND (non emergency) is for serious but less time critical situations. It allows a physician to treat an individual patient who doesn’t qualify for ongoing trials. While it requires a formal application, the FDA often reviews these requests very quickly, much faster than the standard 30 day period. For both pathways, the drug manufacturer must agree to provide the product.

    Navigating these regulations requires deep expertise. The team at Curebase can provide the regulatory support needed to manage these complex submissions, ensuring patients get access to potentially life saving therapies without delay.

    The Bedrock of Patient Protection

    Underpinning every single clinical trial authorization are the core principles of ethical oversight and voluntary participation. In the US, these are enshrined in the Code of Federal Regulations.

    Understanding IRB Approval and Informed Consent

    IRB approval from an Institutional Review Board is the ethical green light for a study. The IRB confirms the trial is ethically sound and that participant risks are minimized.

    Informed consent is the process of ensuring that every participant voluntarily agrees to join a study with a full understanding of its purpose, procedures, risks, and benefits. This is more than a signature on a form; it’s an ongoing dialogue between the research team and the participant, supported by patient engagement tools.

    The Key Regulations: 21 CFR Parts 312, 50, and 56

    Three sections of the US Code of Federal Regulations form the legal foundation for clinical trials:

    • 21 CFR Part 312: The rulebook for Investigational New Drug Applications, covering everything from submission contents to sponsor responsibilities.
    • 21 CFR Part 50: The regulations for protecting human subjects, which define the essential elements of informed consent.
    • 21 CFR Part 56: The rules governing the function, operation, and authority of Institutional Review Boards (IRBs).

    Compliance with these regulations is mandatory. Modern trial platforms, like those developed by Curebase, help ensure every step of the process is compliant, from managing IRB documentation to deploying secure electronic consent.

    Frequently Asked Questions About Clinical Trial Authorization

    What is the main purpose of a clinical trial authorization?

    The primary goal of a clinical trial authorization is to protect the safety and welfare of human participants. Regulators review the available scientific evidence to ensure a proposed study is reasonably safe and ethically justified before it begins.

    How long does it take to get a clinical trial authorization?

    Timelines vary widely. In the UK, the combined review process aims for a decision within 30 days for most applications, with an average approval time of 41 days. In the US, an IND goes into effect after 30 days if the FDA does not issue a clinical hold. The EU’s new coordinated process also has defined, harmonized timelines.

    What’s the difference between an IND in the US and a CTA in the EU or UK?

    They serve the same fundamental purpose but operate under different regulatory frameworks. An IND is the application to the US FDA, while a Clinical Trial Authorisation (CTA) is the approval required from the UK’s MHRA. In the EU, authorization is now handled through a single application via the CTIS portal for multiple countries.

    Can a clinical trial start without ethics committee approval?

    No. Independent ethics committee approval (from a REC or IRB) is a mandatory legal and ethical requirement in virtually every country worldwide. No study can enroll participants without it.

    What is a “clinical hold”?

    A clinical hold is an order issued by the FDA to delay or stop a proposed clinical trial. It is issued within the 30 day review period if the agency identifies significant safety concerns or other deficiencies in the IND application.

    How has the EU’s CTR simplified multinational trials?

    The Clinical Trial Regulation (CTR) created a single, centralized submission and assessment process through the CTIS portal. This allows sponsors to apply for clinical trial authorization in multiple EU countries with one application, eliminating redundant paperwork and harmonizing review timelines.